1. Associations of pulmonary microvascular blood volume with per cent emphysema and CT emphysema subtypes in the community: the MESA Lung study.
- Author
-
Hermann EA, Motahari A, Hoffman EA, Sun Y, Allen N, Angelini ED, Bertoni AG, Bluemke DA, Gerard SE, Guo J, Kaczka DW, Laine A, Michos E, Nagpal P, Pankow JS, Sack CS, Smith B, Stukovsky KH, Watson KE, Wysoczanski A, and Barr RG
- Abstract
Background: Pulmonary microvasculature alterations are implicated in emphysema pathogenesis, but the association between pulmonary microvascular blood volume (PMBV) and emphysema has not been directly assessed at scale, and prior studies have used non-specific measures of emphysema., Methods: The Multi-Ethnic Study of Atherosclerosis Lung Study invited participants recruited from the community without renal impairment to undergo contrast-enhanced dual-energy CT. Pulmonary blood volume was calculated by material decomposition; PMBV was defined as blood volume in the peripheral 2 cm of the lung. Non-contrast CT was acquired to assess per cent emphysema and novel CT emphysema subtypes, which include the diffuse emphysema subtype and small-airways-related combined bronchitic-apical emphysema subtype. Generalised linear regression models included age, sex, race/ethnicity, body size, smoking, total lung volume and small airway count., Results: Among 495 participants, 53% were never-smokers and the race/ethnic distribution was 35% white, 31% black, 15% Hispanic and 18% Asian. Mean PMBV was 352±120 mL; mean per cent emphysema was 4.95±4.75%. Lower PMBV was associated with greater per cent emphysema (-0.90% per 100 mL PMBV, 95% CI: -1.29 to -0.51). The association was of larger magnitude in participants with 10 or more pack-years smoking and airflow obstruction, but present among participants with no smoking history or airflow limitation, and was specific to the diffuse CT emphysema subtype (-1.48% per 100 mL PMBV, 95% CI: -2.31 to -0.55)., Conclusion: In this community-based study, lower PMBV was associated with greater per cent emphysema, including in participants without a smoking history or airflow limitation, and was specific to the diffuse CT emphysema subtype., Competing Interests: Competing interests: EAHo is a founder and shareholder of VIDA Diagnostics, which makes the software used for secondary per cent emphysema measures in this article. YS and NA report receiving grants from the NIH. JG is a shareholder of VIDA Diagnostics and reports receiving grants from the NIH. DWK acknowledges grant support from the US Department of Defense and ZOLL Medical Corporation for work unrelated to this study, is a co-founder and shareholder of OscillaVent, and is listed as a co-inventor on US and European patents related to multi-frequency oscillatory ventilation. Unrelated to this work, EDM reports consulting fees paid by Amgen, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Esperion, Medtronic, Merck, Novo Nordisk, Novartis, New Amsterdam and Pfizer. Unrelated to this work, PN reports receiving grant funding from GE Healthcare, consulting fees from Cannon, honoraria from the Society of Cardiovascular CT and American Society of Nuclear Cardiology, as well as owning stock in Moderna. BS reports receiving grants from the NIH, Canadian Institutes of Health Research, Fonds de la recherche en santé du Québec and the Research Institute of the McGill University Health Centre. RGB reports receiving grants from the COPD Foundation, the US Environmental Protection Agency, the American Lung Association and the NIH., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF